The FDA Just Lost Its Boss (Again). Here's Why Biotech Is Celebrating.

Third, drug rejections. This is where the biotech industry turned hostile. The FDA rejected Replimune's melanoma therapy RP1 due to insufficient evidence from a single-arm trial design, rejected Capricor's treatment for Duchenne muscular dystrophy, and denied Disc Medicine's bitopertin for a rare disease (despite the drug receiving a priority voucher).

Rare-disease drugmakers complained that reviews were wildly inconsistent. One company might get the fast track while another, with similar data, hit a brick wall. The industry's frustration boiled over into something unusual: they wanted the top regulator gone.

The Internal Meltdown

Makary's management style didn't help. He brought in Vinay Prasad, a controversial figure in vaccine policy, as Director of the Center for Biologics Evaluation and Research. Prasad departed at the end of April. Richard Pazdur, a veteran cancer regulator who'd been at the FDA for decades, resigned in December 2025, publicly citing a breach in the traditional "wall" between the commissioner's office and review staff.

That wall exists for a reason. It's supposed to keep political pressure from contaminating scientific decisions. When the person who reviews cancer drugs says the wall has been breached, people notice.

Staff morale plummeted. Experienced scientists left. The agency's workforce had already been slashed by thousands under Kennedy's HHS restructuring. What remained was an FDA running hot on ambition but short on institutional knowledge.

Why the Market Is Cheering

Normally, firing the head of the FDA would spook investors. Regulatory uncertainty is supposed to be the enemy of drug development. But the market's reaction tells a different story.

Biotech companies with drugs stuck in Makary's rejection pile see a second chance. Analysts at Intellectia.AI framed the stock surges as "market optimism regarding regulatory improvements under new leadership." The thinking: a new commissioner might bring consistency back to reviews, clearing the path for stalled approvals.

Meanwhile, M&A activity hasn't slowed down. Full-year forecasts project $140 to $160 billion in total deal value. Big pharma is buying innovation faster than ever, and acquirers care less about who sits in the commissioner's chair than whether their targets can eventually get drugs approved.

The Real Risk Nobody's Pricing In

But there's a catch. Several high-profile decisions are still pending: a COVID prevention drug (June 16), a smoking cessation pill (June 20), and baxdrostat for treatment-resistant hypertension in Q2. CagriSema, Novo Nordisk's next-generation obesity combo, is expected sometime this year.

Leadership transitions create gaps. Since 2009, the FDA has had eight acting commissioners filling vacuums between confirmed leaders. Those gaps typically last three to six months. During that time, bold decisions get delayed. Staff default to caution. Timelines slip.

MassBio CEO Kendalle Burlin O'Connell called FDA leadership instability a "significant and ongoing concern," noting that companies face "shifting regulatory signals, loss of experienced scientific staff, and continued turnover" that complicate long-term planning.

She's right to worry. The biotech industry is pricing in a better future commissioner. But what it's getting, at least for the next several months, is a rudderless ship navigating some of the most consequential drug decisions of the year.

What Happens Next

The firing isn't final yet. Trump has changed his mind before, and Makary's allies could push back. But the political math is brutal: when your boss, your boss's boss, your industry, your staff, and the voters your party needs all want you gone, the question isn't if but when.

If Makary does leave, his legacy will be contradictory. He genuinely modernized parts of the FDA (AI reviews, food safety reforms, faster approvals for priority drugs). But he also politicized decisions, alienated scientists, and created an environment where drugmakers couldn't predict whether their therapies would get a fair shake.

In the end, the FDA's job is boring by design. It's supposed to be the place where science wins and politics loses. Makary tried to be a disruptor in an institution that rewards consistency. The market's reaction to his potential firing says everything: sometimes the most bullish thing that can happen to biotech is a regulator getting out of the way.

Amgen Just Bet on a Computer That Doesn't Fully Exist Yet

Quantinuum, a quantum computing company backed by Amgen and valued at $10 billion, just filed for what could be the largest quantum IPO ever. The real story: Amgen is betting quantum computers can fundamentally redesign how drugs get discovered.